beta-lapachone has been researched along with Prostatic Neoplasms in 13 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "β-Lap killed prostate cancer cells by NAD(P)H:quinone oxidoreductase 1 (NQO1) metabolic bioactivation, triggering a massive induction of reactive oxygen species, irreversible DNA single-strand breaks (SSB), poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, NAD(+)/ATP depletion, and μ-calpain-induced programmed necrosis." | 1.36 | Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. ( Bey, EA; Boothman, DA; Dong, Y; Gao, J; Hsieh, JT; Kabbani, W; Li, LS; Xie, XJ; Yan, J, 2010) |
| "beta-Lapachone killed three different prostate cancer cell lines in an NAD(P)H:quinone oxidoreductase-1-dependent manner." | 1.35 | Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. ( Bey, EA; Blanco, E; Boothman, DA; Bornmann, WG; Chin, SF; Dong, Y; Gao, J; Kabbani, W; Xie, XJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, X | 1 |
| Kasselouri, A | 1 |
| Vergnaud-Gauduchon, J | 1 |
| Rosilio, V | 1 |
| Lien, YC | 1 |
| Kung, HN | 1 |
| Lu, KS | 1 |
| Jeng, CJ | 1 |
| Chau, YP | 2 |
| Dong, Y | 2 |
| Chin, SF | 1 |
| Blanco, E | 1 |
| Bey, EA | 2 |
| Kabbani, W | 2 |
| Xie, XJ | 2 |
| Bornmann, WG | 2 |
| Boothman, DA | 5 |
| Gao, J | 2 |
| Li, LS | 1 |
| Yan, J | 1 |
| Hsieh, JT | 1 |
| Choi, YH | 2 |
| Kang, HS | 1 |
| Yoo, MA | 1 |
| Lee, JH | 1 |
| Cheong, J | 1 |
| Park, YM | 1 |
| Suzuki, M | 1 |
| Amano, M | 1 |
| Choi, J | 1 |
| Park, HJ | 1 |
| Williams, BW | 1 |
| Ono, K | 1 |
| Song, CW | 1 |
| Planchon, SM | 2 |
| Wuerzberger, S | 1 |
| Frydman, B | 1 |
| Witiak, DT | 1 |
| Hutson, P | 1 |
| Church, DR | 1 |
| Wilding, G | 1 |
| Li, CJ | 1 |
| Wang, C | 1 |
| Pardee, AB | 1 |
| Don, MJ | 1 |
| Chang, YH | 1 |
| Chen, KK | 1 |
| Ho, LK | 1 |
| Tagliarino, C | 2 |
| Pink, JJ | 2 |
| Dubyak, GR | 1 |
| Nieminen, AL | 1 |
| Varnes, ME | 1 |
| Kumi-Diaka, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Arm, Open-label Pilot Trial Examining the Effects of Pau d' Arco on Primary Dysmenorrhea in Reproductive Age Women[NCT04245540] | Early Phase 1 | 12 participants (Actual) | Interventional | 2019-07-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for beta-lapachone and Prostatic Neoplasms
| Article | Year |
|---|---|
Assessment of various formulation approaches for the application of beta-lapachone in prostate cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cyclodextrins; Dru | 2020 |
Involvement of endoplasmic reticulum stress and activation of MAP kinases in beta-lapachone-induced human prostate cancer cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Calpain; Caspase Inhibitors; Caspases; Cell Line, Tumor; | 2008 |
Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Implants; Humans; Male; Mice; | 2009 |
Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
Topics: Animals; Apoptosis; Cell Death; Colony-Forming Units Assay; Comet Assay; Dicumarol; DNA Damage; DNA, | 2010 |
Suppression of human prostate cancer cell growth by beta-lapachone via down-regulation of pRB phosphorylation and induction of Cdk inhibitor p21(WAF1/CIP1).
Topics: Antineoplastic Agents; Apoptosis; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cell Line, | 2003 |
Down-regulation of cyclooxygenase-2 and telomerase activity by beta-lapachone in human prostate carcinoma cells.
Topics: Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Down-Regulation; Humans; Male; Naphthoquinones; Prost | 2005 |
Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro.
Topics: Cell Line, Tumor; Cell Survival; Cesium Radioisotopes; Combined Modality Therapy; Dose-Response Rela | 2006 |
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.
Topics: Apoptosis; Breast Neoplasms; Camptothecin; Cell Division; Dimethyl Sulfoxide; Drug Screening Assays, | 1995 |
Induction of apoptosis by beta-lapachone in human prostate cancer cells.
Topics: Apoptosis; Cell Survival; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Leukemia, Promye | 1995 |
Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the beta-lapachone-induced apoptosis of human prostate cancer cells.
Topics: Antibiotics, Antineoplastic; Antioxidants; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Ca | 2001 |
Calcium is a key signaling molecule in beta-lapachone-mediated cell death.
Topics: 4-Nitroquinoline-1-oxide; Adenosine Triphosphate; Apoptosis; Blotting, Western; Breast Neoplasms; Ca | 2001 |
beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3.
Topics: Antibiotics, Antineoplastic; Apoptosis; Camptothecin; Caspases; Dicumarol; Enzyme Inhibitors; Humans | 2001 |
Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and beta-lapachone.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Apoptosis; Cell Division; Drug Synergism; Drug Therapy, | 2002 |